BioLineRx Ltd. (TLV: BLRX)
Israel
· Delayed Price · Currency is ILS · Price in ILA| Market Cap | 69.59M |
| Revenue (ttm) | 81.75M |
| Net Income (ttm) | -74.04M |
| Shares Out | 1.20B |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 103,002 |
| Open | 5.80 |
| Previous Close | 5.80 |
| Day's Range | 5.80 - 5.90 |
| 52-Week Range | 5.30 - 40.60 |
| Beta | 0.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 19, 2025 |
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of ski... [Read more]
News
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ETCompany ParticipantsJohn Lacey - Head of IR & Corporate...
BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M
BioLineRx press release (BLRX): Q3 GAAP EPS of $0.00 beats by $0.07. Revenue of $4.94M misses by $0.35M. As of September 30, 2024, the company had cash,
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
- Executed license agreement with Ayrmid Ltd. for APHEXDA ® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 mi...
Earnings Scheduled For November 25, 2024
Companies Reporting Before The Bell • Alarum Technologies (NASDAQ: ALAR) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. • BioLine Rx (NASDAQ: BLRX) is expecte...
BioLineRx Q3 2024 Earnings Preview
BioLineRx (BLRX) is set to report Q3 earnings on Nov 25. Consensus estimates are -$0.11 EPS and $5.29M revenue.
BioLineRx inks licensing deal, share purchase agreement
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% ...
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a ...
BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide
BioLineRx receives patent allowance for motixafortide in the U.S., extending intellectual property protection through December 2041.
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
– Allowance strengthens company's intellectual property estate and extends motixafortide patent protection in the U.S. through December 2041 – TEL AVIV, Israel , Oct. 16, 2024 /PRNewswire/ -- BioLineR...
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass. , Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript
BioLineRx GAAP EPS of $0.00, revenue of $5.39M
Read about biolinerx's Q2 financial results - GAAP EPS of $0.00 and revenue of $5.39M.
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60...
biolinerx Q2 Earnings Preview
biolinerx (BLRX) to announce Q2 earnings on August 15th.
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 8, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites - - New trial to ex...
BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q1 2024 Earnings Call Transcript May 28, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President...
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Steady growth in APHEXDA ® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem ce...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated 7 of 11 patients in the pilot phase experienced a partial response, w...
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 22, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel , May 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies...
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
- Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia - TEL AVIV, Israel , May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company...
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
TEL AVIV, Israel , April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease...